Page 2186 - Williams Hematology ( PDFDrive )

2160 Part XII: Hemostasis and Thrombosis Chapter 125: Hereditary Fibrinogen Abnormalities 2161

73. Schuepbach RA, Meili EO, Schneider E, et al: Lepirudin therapy for thrombotic compli- 86. Lefebvre P, Velasco PT, Dear A, et al: Severe hypodysfibrinogenemia in compound
cations in congenital afibrinogenaemia. Thromb Haemost 91:1044, 2004. heterozygotes of the fibrinogen AalphaIVS4 + 1G→T mutation and an AalphaGln328
74. Radulovic V, Baghaei F, Blixter IF, et al: Comparable effect of recombinant and plasma- truncation (fibrinogen Keokuk). Blood 103:2571, 2004.
derived human fibrinogen concentrate on ex vivo clot formation after cardiac surgery. 87. Meyer M, Dietzel H, Kaetzel R, et al: Fibrinogen Leipzig II (gamma351Gly→Ser and
J Thromb Haemost 10:1696, 2012. gamma82Ala→Gly): Hypodysfibrinogenaemia due to two independent amino acid sub-
75. Haverkate F, Samama M: Familial dysfibrinogenemia and thrombophilia. Report on a stitutions within the same polypeptide chain. Thromb Haemost 98:903, 2007.
study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 73:151, 1995. 88. Ridgway HJ, Brennan SO, Faed JM, George PM: Fibrinogen Otago: A major alpha
76. Casini A, Blondon M, Lebreton A, et al: Natural history of patients with congenital chain truncation associated with severe hypofibrinogenaemia and recurrent miscar-
dysfibrinogenemia. Blood 125:553, 2015. riage. Br J Haematol 98:632, 1997.
77. Rosenberg JB, Newman PJ, Mosesson MW, et al: Paris I dysfibrinogenemia: A point 89. Koopman J, Haverkate F, Grimbergen J, et al: Fibrinogen Marburg: A homozygous case
mutation in intron 8 results in insertion of a 15 amino acid sequence in the fibrinogen of dysfibrinogenemia, lacking amino acids A alpha 461–610 (Lys 461 AAA→stop TAA).
gamma-chain. Thromb Haemost 69:217, 1993. Blood 80:1972, 1992.
78. Hamano A, Mimuro J, Aoshima M, et al: Thrombophilic dysfibrinogen Tokyo V with 90. Ding Q, Ouyang Q, Xi X, et al: Maternal chromosome 4 heterodisomy/isodisomy
the amino acid substitution of gammaAla327Thr: Formation of fragile but fibrinolysis- and Bβ chain Trp323X mutation resulting in severe hypodysfibrinogenaemia. Thromb
resistant fibrin clots and its relevance to arterial thromboembolism. Blood 103:3045, 2004. Haemost 108:654, 2012.
79. Uemichi T, Liepnieks JJ, Benson MD: Hereditary renal amyloidosis with a novel variant 91. Hayes T: Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 126:1387, 2002.
fibrinogen. J Clin Invest 93:731, 1994. 92. Uemichi T, Liepnieks JJ, Benson MD: Hereditary renal amyloidosis with a novel variant
80. Miesbach W, Scharrer I, Henschen A, et al: Inherited dysfibrinogenemia: Clinical fibrinogen. J Clin Invest 93:731, 1994.
phenotypes associated with five different fibrinogen structure defects. Blood Coagul 93. Shapiro SE, Phillips E, Manning RA, et al: Clinical phenotype, laboratory features and
Fibrinolysis 21:35–40, 2010. genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 160:220,
81. Koopman J, Haverkate F, Briet E, Lord ST: A congenitally abnormal fibrinogen (Vlissin- 2013.
gen) with a 6-base deletion in the gamma-chain gene, causing defective calcium bind- 94. Miesbach W, Schenk J, Alesci S, Lindhoff-Last E: Comparison of the fibrinogen Clauss
ing and impaired fibrin polymerization. J Biol Chem 266:13456, 1991. assay and the fibrinogen PT derived method in patients with dysfibrinogenemia.
82. Casini A, De Maistre E, Casini-Stuppi V, et al: Fibrinogen Geneva II: A new congeni- Thromb Res 126:e428, 2010.
tally abnormal fibrinogen alpha chain (Gly17Asp) with a review of similar mutations 95. Galanakis DK, Neerman-Arbez M, Brennan S, et al: Thromboelastographic pheno-
resulting in abnormal knob A. Blood Coagul Fibrinolysis 25:280, 2014. types of fibrinogen and its variants: Clinical and non-clinical implications. Thromb Res
83. Hirota-Kawadobora M, Terasawa F, Yonekawa O, et al: Fibrinogens Kosai and Ogasa: 133:1115, 2014.
Bbeta15Gly→Cys (GGT→TGT) substitution associated with impairment of fibrinopep- 96. Marchi R, Meyer M, de Bosch N, et al: Biophysical characterization of fibrinogen Cara-
tide B release and lateral aggregation. J Thromb Haemost 1:275, 2003. cas I with an Aalpha-chain truncation at Aalpha-466 Ser: Identification of the mutation
84. Siebenlist KR, Mosesson MW, Meh DA, et al: Coexisting dysfibrinogenemia (gam- and biophysical characterization of properties of clots from plasma and purified fibrin-
maR275C) and factor V Leiden deficiency associated with thromboembolic disease ogen. Blood Coagul Fibrinolysis 15:285, 2004.
(fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 11:293, 2000. 97. Marchi RC, Meyer MH, de Bosch NB, et al: A novel mutation (deletion of Aalpha-Asn
85. Okumura N, Terasawa F, Hirota-Kawadobora M, et al: A novel variant fibrinogen, dele- 80) in an abnormal fibrinogen: Fibrinogen Caracas VI. Consequences of disruption of
tion of Bbeta111Ser in coiled-coil region, affecting fibrin lateral aggregation. Clin Chim the coiled-coil for the polymerization of fibrin: Peculiar clot structure and diminished
Acta 365:160, 2006. stiffness of the clot. Blood Coagul Fibrinolysis 15:559, 2004.

Kaushansky_chapter 125_p2151-2162.indd 2161 9/18/15 5:48 PM